Key result
NOACs and warfarin showed no significant difference in preventing stroke or systemic embolism in Asian octogenarian patients with atrial fibrillation (1.16 vs. 2.98 events per 100 patient-years, p=0.46).
Why the study?
Do non-vitamin K antagonist oral anticoagulants reduce stroke or systemic embolism compared to warfarin in Korean octogenarian patients with non-valvular atrial fibrillation?
Cohort (n=293)
No
Do non-vitamin K antagonist oral anticoagulants reduce stroke or systemic embolism compared to warfarin in Korean octogenarian patients with non-valvular atrial fibrillation?
Absolute Event Rate: 1.16% vs 2.98%
p-value: p=0.46
In Korean octogenarian patients with non-valvular atrial fibrillation, NOACs and warfarin showed comparable efficacy and safety, though major bleeding rates were high in both groups.
No difference observed does not support changing anticoagulation choices; leaves open need for randomized confirmation in Asian octogenarians.
BACKGROUND: The efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asian octogenarian atrial fibrillation (AF) patients have not been established in a real-world setting. We aimed to evaluate the efficacy and safety of NOACs and warfarin in Korean octogenarian patients. METHODS: A total of 293 consecutive patients aged ≥ 80 years with non-valvular AF who had taken either NOACs (148 cases, 50.5%) or warfarin (145 cases, 49.5%) were retrospectively reviewed. The efficacy outcome was the composite of stroke or systemic embolism. The safety outcome was major bleeding. RESULTS: The follow-up duration was 375 patient-years (172 patient-years with NOACs and 203 patient-years with warfarin). Patients on NOACs were slightly older (P = 0.006) and had slightly higher HAS-BLED scores (P = 0.034). The efficacy of both anticoagulants was high (1.16% for NOACs vs. 2.98% for warfarin per 100 patient-years, P = 0.46). The safety outcome was relatively high in both NOACs and warfarin groups (8.96% vs. 12.46%, P = 0.29). The efficacy and safety outcomes tended to decrease non-significantly in low dose NOACs than in common dose NOACs or warfarin (0.85% vs. 1.84% vs. 2.98% in efficacy outcome, P = 0.69; and 6.97% vs. 13.29% vs. 12.46% in safety outcome, P = 0.34). CONCLUSIONS: NOACs were highly effective for prevention of stroke or systemic embolism in Asian octogenarian AF patients. However, major bleeding occurred excessively high in both anticoagulant groups. Further study is required on the optimal anticoagulant regimen in octogenarian population.
No takes yet. Share an insight, caveat, or question.
Kwon et al. (2016) conducted a cohort in Non-valvular atrial fibrillation (n=293). Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Warfarin was evaluated on Composite of stroke or systemic embolism (p=0.46). NOACs and warfarin showed no significant difference in preventing stroke or systemic embolism in Asian octogenarian patients with atrial fibrillation (1.16 vs. 2.98 events per 100 patient-years, p=0.46).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: